The phase III IMbrave150 study evaluating Tecentriq in combination with Avastin in people with unresectable hepatocellular carcinoma met its co-primary endpoints of overall survival and progression-free survival, compared with standard-of-care sorafenib.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
